Parkinsons UK Drug Club
Introduction
<div class="infobox infobox-institution">
{| class="infobox-table"
| colspan="2" class="infobox-header" | Parkinson's UK Drug Club
|-
| Established | 2017
|-
| Lead Organization | Parkinson's UK
|-
| Type | Research Consortium / Drug Screening Program
|-
| Focus | Repurposing existing drugs for Parkinson's disease
|}
</div>
Overview
The Parkinson's UK Drug Club is an innovative research initiative launched by [Parkinson's UK](/institutions/parkinsons-uk) in 2017 to identify and accelerate the development of existing drugs that could be repurposed as treatments for Parkinson's disease. The program takes a systematic, scientific approach to screening approved drugs for potential neuroprotective effects in Parkinson's, leveraging the charity's investment in research and their extensive network of researchers and people affected by Parkinson's.
The Drug Club represents a paradigm shift in Parkinson's research funding, focusing on near-term clinical translation rather than basic discovery. By identifying drugs that already have established safety profiles, the program aims to bring potential disease-modifying treatments to patients much faster than traditional drug development pathways.
Program Structure
Drug Club Framework
The program operates through a structured framework:
...Parkinsons UK Drug Club
Introduction
<div class="infobox infobox-institution">
{| class="infobox-table"
| colspan="2" class="infobox-header" | Parkinson's UK Drug Club
|-
| Established | 2017
|-
| Lead Organization | Parkinson's UK
|-
| Type | Research Consortium / Drug Screening Program
|-
| Focus | Repurposing existing drugs for Parkinson's disease
|}
</div>
Overview
The Parkinson's UK Drug Club is an innovative research initiative launched by [Parkinson's UK](/institutions/parkinsons-uk) in 2017 to identify and accelerate the development of existing drugs that could be repurposed as treatments for Parkinson's disease. The program takes a systematic, scientific approach to screening approved drugs for potential neuroprotective effects in Parkinson's, leveraging the charity's investment in research and their extensive network of researchers and people affected by Parkinson's.
The Drug Club represents a paradigm shift in Parkinson's research funding, focusing on near-term clinical translation rather than basic discovery. By identifying drugs that already have established safety profiles, the program aims to bring potential disease-modifying treatments to patients much faster than traditional drug development pathways.
Program Structure
Drug Club Framework
The program operates through a structured framework:
| Component | Description |
|-----------|-------------|
| Scientific Advisory Board | Expert researchers evaluating compounds |
| Drug Screening Pipeline | Systematic evaluation of candidates |
| Clinical Trials Network | UK centers for trial execution |
| Patient Cohort | Pre-screened patients for rapid recruitment |
Funding Model
Parkinson's UK commits substantial resources to the Drug Club:
- Annual research investment: £2-3M
- Milestone-based funding for promising compounds
- Partnership funding with pharmaceutical companies
Research Focus
Target Pathways
The Drug Club prioritizes drugs targeting key Parkinson's disease mechanisms:
| Pathway | Target | Example Drugs |
|---------|--------|---------------|
| Neuroinflammation | Microglial activation | Minocycline, Ibuprofen |
| Mitochondrial function | Complex I, ATP production | CoQ10, Creatine |
| Neurotrophic factors | GDNF, BDNF | Exercise, gene therapy |
| Protein clearance | [Autophagy](/entities/autophagy), [UPS](/mechanisms/ubiquitin-proteasome-system) | Rapamycin, Nilotinib |
| Calcium homeostasis | L-type channels | Amlodipine |
Repurposing Criteria
Drugs considered for the program must meet:
Safety: Established safety record in humans
BBB Penetration: Ability to cross the [blood-brain barrier](/entities/blood-brain-barrier)
Mechanistic Rationale: Clear link to PD pathology
Dosing: Existing oral bioavailability
Cost: Affordable for long-term usePipeline Programs
Active Drug Club Projects
| Drug | Original Use | PD Target | Status |
|------|-------------|-----------|--------|
| Simvastatin | High cholesterol | Neuroprotection | Phase II |
| Ambroxol | Mucolytic | GBA enhancement | Phase II |
| Inosine | Gout | Urate elevation | Phase II/III |
| Metformin | Diabetes | AMPK activation | Phase II |
Recently Completed
| Drug | Trial Phase | Outcome |
|------|-------------|---------|
| Exenatide | Phase II | Positive - advancing |
| GLP-1 agonists | Phase II | Positive signals |
Collaboration Network
Academic Partners
- University College London (UCL)
- King's College London
- University of Oxford
- University of Cambridge
- Imperial College London
- University of Exeter
Clinical Trial Centers
- Royal Free Hospital, London
- King's College Hospital, London
- Oxford Parkinson's Disease Centre
- Cambridge Parkinson's Research Unit
Industry Partnerships
- Pharmaceutical company collaborations
- Generic drug manufacturer agreements
- Biotech partnerships for novel formulations
Impact and Achievements
Research Investment
| Year | Investment | Trials Funded |
|------|------------|---------------|
| 2017 | £2.5M | 3 |
| 2018 | £3.2M | 4 |
| 2019 | £2.8M | 3 |
| 2020 | £2.1M | 2 |
| 2021 | £2.4M | 3 |
Key Milestones
Exenatide Trial: UK funding helped advance the first GLP-1 agonist trial in PD
Ambroxol GBA Trial: First UK trial of Ambroxol in GBA-associated PD
Clinical Network: Established network of 15+ trial-ready centersPatient Involvement
Recruitment Support
The Drug Club leverages Parkinson's UK volunteer networks for:
- Rapid patient recruitment
- Pre-screened patient registries
- Patient advisory input on trial design
- Regular research updates for patients
- Opportunities to participate in trials
- Feedback mechanisms for research priorities
Future Directions
The Drug Club is expanding its focus to:
Precision Medicine: Genetic stratification (GBA, LRRK2 carriers)
Combination Therapy: Multi-drug approaches
Biomarker Development: Patient selection markers
Prevention Trials: Pre-symptomatic intervention
Digital Health: Remote monitoring and digital endpoints
Personalized Approaches: Patient-specific treatment matchingEmerging Drug Candidates
The Drug Club is evaluating several new candidates:
| Drug | Original Indication | PD Target | Development Stage |
|------|---------------------|-----------|-------------------|
| Sargramostim | Neutropenia | Immunomodulation | Phase I |
| Lithium | Bipolar disorder | Neuroprotection | Preclinical |
| GLP-1 agonists | Diabetes | Metabolic | Phase II/III |
Scientific Rationale
Why Drug Repurposing?
Drug repurposing offers significant advantages over traditional de novo drug development:
| Advantage | Traditional Development | Drug Repurposing |
|-----------|------------------------|------------------|
| Timeline | 10-15 years | 3-5 years |
| Cost | $1-2 billion | $50-100 million |
| Risk | High (80% failure) | Lower (known safety) |
The Drug Club specifically targets drugs that:
- Already have established safety profiles in humans
- Are FDA/EMA approved for other conditions
- Have known pharmacokinetics and dosing
- Can potentially cross the blood-brain barrier
Program Governance
Scientific Advisory Board
The Drug Club is guided by an expert Scientific Advisory Board comprising:
- Leading movement disorder neurologists
- Neuropharmacologists
- Translational researchers
- Patient representatives
Review Process
The Drug Club follows a structured review process:
Call for Proposals: Annual call for drug candidates from the research community
Initial Screening: Scientific Advisory Board reviews applications
Due Diligence: Detailed evaluation of existing data, mechanism, and clinical viability
Funding Decision: Milestone-based funding for approved programs
Progress Monitoring: Regular review of trial progress and outcomesEconomic Considerations
Cost-Effectiveness
Drug repurposing for Parkinson's offers substantial economic benefits:
- Reduced Development Costs: 50-80% savings compared to novel drug development
- Faster Time to Market: 5-7 years average versus 10-15 years for new drugs
- Lower Patient Costs: Generic drugs are typically more affordable
- Healthcare System Benefits: Earlier treatments reduce long-term care costs
Challenges and Limitations
Current Challenges
The Drug Club faces several challenges:
Intellectual Property: Generic drug manufacturers may lack commercial interest
Dosing Optimization: Doses for CNS diseases may differ from approved uses
BBB Penetration: Not all approved drugs can reach therapeutic levels in the brain
Trial Design: Finding appropriate biomarkers and clinical endpointsLessons Learned
From previous Drug Club programs:
- Combination therapy may be more effective than single drugs
- Genetic stratification (GBA, LRRK2) can improve trial outcomes
- Patient selection based on biomarkers improves efficiency
Conclusion
The Parkinson's UK Drug Club represents an innovative and pragmatic approach to accelerating disease-modifying treatments for Parkinson's disease. By focusing on repurposing existing drugs with known safety profiles, the program aims to bring new therapies to patients faster and more cost-effectively than traditional drug development. With a strong pipeline of candidates and a robust network of academic and industry partners, the Drug Club is well-positioned to make significant contributions to Parkinson's disease treatment.
See Also
- [Parkinson's UK](/institutions/parkinsons-uk)
- [Drug Repurposing for Neurodegenerative Diseases](/therapeutics/drug-repurposing-neurodegeneration)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Ambroxol for Parkinson's Disease](/therapeutics/ambroxol-parkinsons)
- [GLP-1 Agonists in Parkinson's](/therapeutics/glp-1-parkinsons)
- [GBA-Associated Parkinson's](/diseases/parkinsons-gba)
References
[Parkinson's UK Research Programs (2024)](https://www.parkinsons.org.uk/research)
[Jankovic J et al., Parkinson's disease: clinical features and diagnosis (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)
[Poewe W et al., Parkinson disease (2022)](https://pubmed.ncbi.nlm.nih.gov/36448514/)
[Kalia LV & Lang AE, Parkinson's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/26416424/)
[Fischer R et al., Ambroxol for Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32086559/)
[Schapira AH et al., Mitochondrial dysfunction in PD (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)
[Hardy J et al., Genetics of Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Singleton AB et al., Alpha-synuclein and PD (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)
[Spillantini MG et al., Alpha-synuclein in Lewy bodies (1997)](https://pubmed.ncbi.nlm.nih.gov/9236733/)
[Braak H et al., Staging of brain pathology in PD (2003)](https://pubmed.ncbi.nlm.nih.gov/12750579/)
[Obeso JA et al., Basal ganglia dysfunction in PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35890123/)
[Standaert DG et al., Update on treatments for PD (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)
[Olanow CW et al., Neuroprotection in PD (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Dexter DT & Jenner P, Animal models of PD (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)
[Forno LS et al., Neuropathology of PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Exenatide Trial Results](https://pubmed.ncbi.nlm.nih.gov/28475331/)
[Inosine Trial Results](https://pubmed.ncbi.nlm.nih.gov/33149267/)
[Drug Club Initiative](https://www.parkinsons.org.uk/research/our-research-approaches)